written on 08.05.2014

Teva could kill 3 birds with one $6B deal for India's Cipla


Last week, Teva CEO Erez Vigodman said the Israeli company was looking to refocus on its generics business, bolster its emerging markets presence and become a major player in the global biosimilars race. And now, he may be eyeing a $6 billion deal that could help accomplish all three goals.